Among the chief discrepancies between the House and Senate health reform proposals is a provision of the House bill that would allow states to negotiate directly with pharmaceutical companies for lower drug prices on behalf of their lowest income seniors — those eligible for both Medicare and Medicaid. House leaders, More…
While we’re on the topic of that $80 billion deal struck between Democratic leaders and the nation’s drug makers, it’s worth clarifying how it came to be. Many in the press have reported that the deal originated in the White House, which is perfectly understandable because More…
On Monday, The New York Times ran a damning story detailing how the nation’s drug makers are hiking their prices ahead of the reform laws winding their way through Congress. The very next day, some powerful House Democrats called for a closer look, asking the Government Accountability Office More…
President Obama today made official an $80 billion deal with the pharmaceutical industry to cut prescription drug costs for the nation’s seniors.
As it is, Medicare patients are forced to pay the full cost for their prescription drugs when annual expenses fall between $2,700 and $6,154. Under the new More…
Two bills introduced in Congress recently stake out rival positions on a key issue related to health care reform. Which approach ultimately prevails will help determine whether the pharmaceutical industry maintains the support that Pfizer CEO Jeffrey Kindler voiced Wednesday for President Obama’s plan’s to overhaul the More…
Pharma Times, news site of the drug industry, is calling the emerging outlines of the Obama health care plan “radical.” Whether that is a good thing or a bad thing, depends on which sector of the industry you talk to.
Makers of generic drugs, for example, are smiling. Kathleen More…
rss